Welcome to our dedicated page for Mobia Medical SEC filings (Ticker: MOBI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Mobia Medical's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Mobia Medical's regulatory disclosures and financial reporting.
Mobia Medical, Inc. Chief Operating Officer Prashant B. Rawat exercised stock options to acquire 15,000 shares of common stock on June 10, 2026. The options were exercised at an exercise price of $3.38 per share, a routine derivative conversion rather than an open-market purchase or sale.
Following the transaction, Rawat directly holds 15,000 shares of common stock and continues to hold 182,243 stock options. The option grant vested 25% on June 27, 2023 and the remainder in 36 substantially equal monthly installments, reflecting standard compensation-related equity vesting.
Mobia Medical, Inc.'s Chief Financial Officer, Curnes Nelson Bunker, purchased 5,000 shares of common stock in an open‑market transaction at a weighted average price of $12.7938 per share on June 9, 2026. Following the purchase, he directly holds 366,997 shares.
The filing also reflects prior restructuring entries tied to entities such as Curnes Fund 2001 and Exceller Hunt Microtransponder 2017, LP, which distributed shares to their members before the company’s initial public offering. Footnotes state Bunker received 58,359 shares in these pro rata in‑kind distributions, which remain subject to IPO lock‑up restrictions.
Mobia Medical reported strong top-line growth but continued sizable losses for the quarter ended March 31, 2026. Revenue rose to $12.1 million from $5.7 million a year earlier, driven by broader adoption of its Vivistim Paired VNS System for chronic stroke recovery.
Operating expenses increased to $26.9 million, mainly from higher selling, general and administrative costs, leading to a net loss of $17.7 million versus $10.7 million last year. Cash and cash equivalents were $55.7 million as of March 31, 2026. Management previously raised going concern doubts, but the May 2026 IPO raised approximately $134.5 million and converted all preferred stock and $40.0 million of convertible notes into common stock, which the company now expects will fund operations for at least one year from issuance of these statements.
Mobia Medical, Inc. disclosure: Synapse Investment and related entities report beneficial ownership of 1,986,072 shares of Common Stock, equal to 6.0% of the class. The filing states these holders share voting and dispositive power over the reported shares.
The reporting parties list their principal business office as c/o SR One Capital Management, LP, Redwood City, CA, and the report was signed pursuant to a power of attorney.
Osage University Partners funds and William Harrington report beneficial ownership of 3,410,899 shares of Mobia Medical common stock, representing 10.3% of the class based on 33,085,391 shares outstanding after the company’s initial public offering.
The position is held through Osage University Partners III and IV, whose general partners share voting and dispositive power, with Harrington as a manager and member of Mobia Medical’s board. The stake arose from multiple preferred stock and note investments that converted into common stock at IPO, plus additional IPO share purchases, and is subject to a 180‑day lock-up and existing registration rights.